Website
News25/Ratings12
News · 26 weeks59-96%
2025-10-262026-04-19
Mix3690d
- Insider12(33%)
- Analyst9(25%)
- Other7(19%)
- SEC Filings6(17%)
- Earnings2(6%)
Latest news
25 items- SECSEC Form PRE 14A filed by uniQure N.V.PRE 14A - uniQure N.V. (0001590560) (Filer)
- ANALYSTuniQure upgraded by Mizuho with a new price targetMizuho upgraded uniQure from Neutral to Outperform and set a new price target of $35.00
- INSIDERChief Customer & Strat Officer O'Keefe Kylie was granted 19,800 units of Ordinary Shares, increasing direct ownership by 19% to 124,800 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERNew insider O'Keefe Kylie claimed ownership of 105,000 units of Ordinary Shares (SEC Form 3)3 - uniQure N.V. (0001590560) (Issuer)
- ANALYSTuniQure upgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts upgraded uniQure from Sector Perform to Outperform and set a new price target of $35.00
- ANALYSTuniQure upgraded by Wells Fargo with a new price targetWells Fargo upgraded uniQure from Equal Weight to Overweight and set a new price target of $60.00
- INSIDERCEO, Managing Director Kapusta Matthew C was granted 70,600 units of Ordinary Shares and sold $132,104 worth of Ordinary Shares (14,581 units at $9.06), increasing direct ownership by 9% to 660,658 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERChief Medical Officer Abi-Saab Walid sold $7,320 worth of Ordinary Shares (808 units at $9.06) and was granted 41,700 units of Ordinary Shares, increasing direct ownership by 27% to 189,669 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERChief Legal Officer Potts Jeannette was granted 35,400 units of Ordinary Shares and sold $30,913 worth of Ordinary Shares (3,412 units at $9.06), increasing direct ownership by 30% to 138,483 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERChief Financial Officer Klemt Christian was granted 39,600 units of Ordinary Shares and sold $108,720 worth of Ordinary Shares (12,000 units at $9.06), increasing direct ownership by 14% to 226,581 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- SECSEC Form 144 filed by uniQure N.V.144 - uniQure N.V. (0001590560) (Subject)
- INSIDERCEO, Managing Director Kapusta Matthew C sold $342,648 worth of Ordinary Shares (34,437 units at $9.95), decreasing direct ownership by 5% to 604,639 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERChief Financial Officer Klemt Christian sold $124,693 worth of Ordinary Shares (12,532 units at $9.95), decreasing direct ownership by 6% to 198,981 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERChief Legal Officer Potts Jeannette sold $85,351 worth of Ordinary Shares (8,578 units at $9.95), decreasing direct ownership by 7% to 106,495 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERChief Medical Officer Abi-Saab Walid sold $16,517 worth of Ordinary Shares (1,660 units at $9.95), decreasing direct ownership by 1% to 148,777 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- ANALYSTuniQure downgraded by Wells Fargo with a new price targetWells Fargo downgraded uniQure from Overweight to Equal Weight and set a new price target of $15.00
- ANALYSTuniQure downgraded by Mizuho with a new price targetMizuho downgraded uniQure from Outperform to Neutral and set a new price target of $12.00
- SECSEC Form 144 filed by uniQure N.V.144 - uniQure N.V. (0001590560) (Subject)
- ANALYSTuniQure downgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts downgraded uniQure from Outperform to Sector Perform and set a new price target of $11.00
- ANALYSTuniQure downgraded by Cantor Fitzgerald with a new price targetCantor Fitzgerald downgraded uniQure from Overweight to Neutral and set a new price target of $9.00
- SECSEC Form 10-K filed by uniQure N.V.10-K - uniQure N.V. (0001590560) (Filer)
- SECuniQure N.V. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - uniQure N.V. (0001590560) (Filer)
- PRuniQure Announces 2025 Financial Results and Provides Recent Company Updates~ Held Type A meeting with FDA to discuss AMT-130 for Huntington's disease; Company evaluating Phase III development considerations and plans to request follow-up Type B meeting in the second quarter of 2026 ~ ~ Completed enrollment of the first cohort in the Phase I/IIa study of AMT-260 in refractory mesial temporal lobe epilepsy, with additional clinical data expected in the first half of 2026 ~ ~ Presented updated Phase I/II data from AMT-191 in Fabry disease showing durable, dose-dependent increases in α-Gal A enzyme activity ~ ~ Cash, cash equivalents and current investment securities of approximately $622.5 million as of December 31, 2025 expected to fund operations into the second
- PRuniQure Provides Regulatory Update on AMT-130 for Huntington's DiseaseLEXINGTON, Mass. and AMSTERDAM, March 02, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the company received final meeting minutes from the U.S. Food and Drug Administration (FDA) regarding a Type A meeting held on January 30, 2026 to discuss AMT-130, an investigational gene therapy for Huntington's disease (HD). The FDA stated that it cannot agree that data from the Phase I/II studies, compared to an external control, are sufficient to provide the primary evidence of effectiveness required to support a marketing application for AMT-130. The FDA strongly
- INSIDERCEO, Managing Director Kapusta Matthew C sold $295,339 worth of Ordinary Shares (12,378 units at $23.86), decreasing direct ownership by 2% to 639,076 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)